AGE-RELATED MACULAR DEGENERATION, PHATOPHYSIOLOGY, CURRENT TREATMENT AND THERAPEUTIC PERSPECTIVES
Authors:
- Patrycja JęDrzejewska-RzezakPJPatrycja JęDrzejewska-Rzezak
- Adam ŻuczekAŻAdam Żuczek
- Kinga DyndalKDKinga Dyndal
- Marcelina BrodaMBMarcelina Broda
- Olga ŻuczekOŻOlga Żuczek
- Katarzyna UrbańskaKUKatarzyna Urbańska
- Izabela SzczapISIzabela Szczap
- Anna HawrylukAHAnna Hawryluk
- Kamil MarzecKMKamil Marzec
- Aleksandra MokrzyckaAMAleksandra Mokrzycka
- Wojciech KupczakWKWojciech Kupczak
- Kinga BujakKBKinga Bujak
Open Access
- 21 December 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (4(48))
Abstract
Age-related macular degeneration (AMD) is a disease leading to severe central vision loss and blindness in people over 60 years. [1] The pathogenesis of this disease is multifactorial and complex interactions of metabolic, functional genetic, and environmental factors - it is not fully known. [2] For the above reasons, the effectiveness of the therapies used is limited. Although the disease involves changes in the anatomical and functional complex, including photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris layer, the essence of the disorder and its earliest stage is the progressive degeneration and atrophv of the RPE cells. leadina conseauentiv to irreversible damaae to photoreceptors. Four processes occurring within the mentioned complex contribute to the development of AMD: lipofuscinogenesis, drusogenesis, inflammation, and neovascularization. [3]Keywords
This publication has 49 references indexed in Scilit:
- Melatonin and Risk of Age-Related Macular DegenerationJAMA Ophthalmology, 2024
- Modeling complex age-related eye diseaseProgress in Retinal and Eye Research, 2024
- Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMDGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is oursGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in EuropeOphthalmology, 2021
- Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration DataOphthalmology, 2020
- Age-related macular degenerationThe Lancet, 2018
- Laser photocoagulation as treatment of non-exudative age-related macular degeneration: state-of-the-art and future perspectivesGraefe's Archive for Clinical and Experimental Ophthalmology, 2017
- Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease StudyJAMA Ophthalmology, 2014
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006